Metastatic rhabdoid meningioma with BRAF V600E mutation and good response to personalized therapy: case report and review of the literature.
Journal: Pediatric Hematology And Oncology
Published:
Abstract
Rhabdoid meningioma is an aggressive phenotype of meningioma, associated with a poor prognosis. We present a very rare case of high-grade meningioma with rhabdoid features that eventually expressed in a coma state. Comprehensive genomic profiling using a Next Generation Sequencing (NGS) assay revealed three genomic alterations: activating BRAF mutation (V600E), loss of CDKN2A/2B, and APC I1307K. After treatment with BRAF inhibitor (dabrafenib), the child's clinical condition improved progressively. After seven months, an MEK inhibitor was added (trametinib).
Authors
Oz Mordechai, Sergey Postovsky, Eugene Vlodavsky, Ayelet Eran, Shlomi Constantini, Eynat Dotan, Emmanuela Cagnano, Myriam Weyl Ben Arush
Relevant Conditions